SCHEMBL4529082

SCHEMBL4529082

Cc1oc(N)nc1-c1cccc(Br)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.45
NPC1 O15118 7/20 0.45
MAPT P10636 4/20 0.45
KDM4E B2RXH2 4/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
ALDH1A1 P00352 4/20 0.45
NPSR1 Q6W5P4 2/20 0.45
GAA P10253 1/20 0.45
HSD17B10 Q99714 2/20 0.44
TP53 P04637 2/20 0.44
MAOB P27338 3/20 0.44
IKBKB O14920 1/20 0.44
HPGD P15428 2/20 0.44
HK1 P19367 1/20 0.44
HKDC1 Q2TB90 1/20 0.44
POLB P06746 1/20 0.44
RXFP1 Q9HBX9 1/20 0.43
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4527722 0.82 NR4A2 (0.50) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4524495 0.81 RAB9A (0.47) RAB9ANPC1MEN1KMT2ASMN1; SMN2
SCHEMBL4523610 0.77 RAB9A (0.45) RAB9ANPC1MAPTKDM4EMEN1
SCHEMBL4526075 0.73 DHFR (0.45) RAB9ANPC1KDM4EMEN1KMT2A
SCHEMBL11385402 0.70 ALDH1A1 (0.46) RAB9ANPC1MAPTKDM4EMEN1
SCHEMBL25177267 0.68 RAB9A (0.69) RAB9ANPC1MAPTKDM4EMEN1
SCHEMBL31043527 0.68 RAB9A (0.69) RAB9ANPC1MAPTKDM4EMEN1
SCHEMBL5479662 0.68 RXFP1 (0.52) RAB9ANPC1MAPTKDM4EMEN1
SCHEMBL28357067 0.68 MAPT (0.51) RAB9ANPC1MAPTKDM4EMEN1
SCHEMBL23162526 0.67 IDO1 (0.56) RAB9ANPC1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018150-A1 5-Ht2b Receptor Antagonists ASTERAND UK LIMITED (GB) 2009-01-15 US disclosed
US-20090018150-A1 5-Ht2b Receptor Antagonists ASTERAND UK LIMITED (GB) 2009-01-15 US disclosed
US-20090018150-A1 5-Ht2b Receptor Antagonists ASTERAND UK LIMITED (GB) 2009-01-15 US disclosed
EP-1648876-A1 5-HT SB 2B /SB RECEPTOR ANTAGONISTS Pharmagene Laboratories Ltd (GB) 2006-04-26 EP disclosed
WO-2005012263-A1 5-HT2B RECEPTOR ANTAGONISTS PHARMAGENE LABORATORIES LIMITED (GB) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018150-A1 5-Ht2b Receptor Antagonists HTR2B, HTR1B, HTR3B RAB9A 1024/4885NPC1 2993/4885MAPT 2855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.